Valeant has room to move on Cephalon price

Valeant Pharmaceuticals' hostile bid for Cephalon is so low that Valeant could raise the offer by 15 percent and still pay less than any drug takeover in history. Report

Suggested Articles

A $300M pandemic ad campaign may be falling apart as HHS employees push back, celebrities balk and agency brass push a rushed timeline, Politico says.

With a pack of drugmakers angling for COVID-19 vaccine approvals in the coming months, the task of global distribution is more important than ever. Wi

"We have a chance to improve our reputation if we deliver on our purpose to find solutions responsibly," GSK CEO Emma Walmsley said.